SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biolase, Inc – ‘10-Q’ for 3/31/20 – ‘EX-10.8’

On:  Friday, 5/8/20, at 3:11pm ET   ·   For:  3/31/20   ·   Accession #:  1564590-20-23480   ·   File #:  1-36385

Previous ‘10-Q’:  ‘10-Q’ on 11/12/19 for 9/30/19   ·   Next:  ‘10-Q’ on 8/14/20 for 6/30/20   ·   Latest:  ‘10-Q’ on 11/9/23 for 9/30/23   ·   28 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/08/20  Biolase, Inc                      10-Q        3/31/20   86:8.5M                                   ActiveDisclosure/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    638K 
 4: EX-10.10    Material Contract                                   HTML     30K 
 2: EX-10.8     Material Contract                                   HTML     63K 
 3: EX-10.9     Material Contract                                   HTML     30K 
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     32K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     32K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     26K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     26K 
21: R1          Document and Entity Information                     HTML     78K 
69: R2          Consolidated Balance Sheets (Unaudited)             HTML    114K 
78: R3          Consolidated Balance Sheets (Unaudited)             HTML     51K 
                (Parenthetical)                                                  
50: R4          Consolidated Statements Of Operations And           HTML     95K 
                Comprehensive Loss (Unaudited)                                   
20: R5          Consolidated Statements Of Redeemable Preferred     HTML     53K 
                Stock and Stockholders' (Deficit) Equity                         
                (Unaudited)                                                      
68: R6          Consolidated Statements Of Cash Flows (Unaudited)   HTML    110K 
77: R7          Description of Business and Basis of Presentation   HTML     47K 
49: R8          Summary of Significant Accounting Policies          HTML     39K 
22: R9          Revenue Recognition                                 HTML    165K 
63: R10         Redeemable Preferred Stock and Stockholders'        HTML    243K 
                (Deficit) Equity                                                 
71: R11         Inventory                                           HTML     46K 
48: R12         Property, Plant, and Equipment                      HTML     67K 
19: R13         Intangible Assets and Goodwill                      HTML     29K 
62: R14         Accrued Liabilities                                 HTML     87K 
70: R15         Debt                                                HTML     98K 
47: R16         Leases                                              HTML     79K 
18: R17         Commitments and Contingencies                       HTML     35K 
61: R18         Segment Information                                 HTML     61K 
72: R19         Concentrations                                      HTML     74K 
42: R20         Income Taxes                                        HTML     31K 
34: R21         Subsequent Event                                    HTML     31K 
60: R22         Summary of Significant Accounting Policies          HTML    219K 
                (Policies)                                                       
86: R23         Revenue Recognition (Tables)                        HTML    206K 
41: R24         Redeemable Preferred Stock and Stockholders'        HTML    247K 
                (Deficit) Equity (Tables)                                        
33: R25         Inventory (Tables)                                  HTML     47K 
59: R26         Property, Plant, and Equipment (Tables)             HTML     66K 
85: R27         Accrued Liabilities (Tables)                        HTML     88K 
43: R28         Debt (Tables)                                       HTML     75K 
32: R29         Leases (Tables)                                     HTML     80K 
15: R30         Segment Information (Tables)                        HTML     62K 
45: R31         Concentrations (Tables)                             HTML    118K 
73: R32         Description of Business and Basis of Presentation   HTML     56K 
                - Additional Information (Detail)                                
64: R33         Revenue Recognition - Additional Information        HTML     34K 
                (Detail)                                                         
16: R34         Summary of Opening and Closing Balances of          HTML     37K 
                Contract Liabilities (Detail)                                    
46: R35         Summary of Disaggregation of Revenues Related to    HTML     32K 
                Geographic Areas (Detail)                                        
74: R36         Summary of Revenues Disaggregated by Timing of      HTML     32K 
                Goods and Services Transferred (Detail)                          
65: R37         Summary of Sales by End Market (Detail)             HTML     32K 
17: R38         Schedule of Revenue and Percentages of Revenue      HTML     49K 
                Sales by Product Line (Detail)                                   
44: R39         Redeemable Preferred Stock and Stockholders'        HTML     79K 
                (Deficit) Equity - Additional Information (Detail)               
29: R40         Classification of Compensation Expense Associated   HTML     37K 
                with Share-Based Payments (Detail)                               
39: R41         Assumptions Used in Estimating Fair Value of Stock  HTML     33K 
                Options Granted (Detail)                                         
80: R42         Summary of Option Activity (Detail)                 HTML     59K 
54: R43         Summary of Unvested Stock Option Activity (Detail)  HTML     46K 
30: R44         Cash Proceeds Along with Fair Value Disclosures     HTML     33K 
                Related to Grants, Exercises and Vested Options                  
                (Detail)                                                         
40: R45         Summary of Unvested Restricted Stock Units          HTML     50K 
                (Detail)                                                         
81: R46         Summary of Warrant Activity (Detail)                HTML     37K 
55: R47         Components of Inventory (Detail)                    HTML     35K 
31: R48         Inventory - Additional Information (Detail)         HTML     28K 
37: R49         Summary of Property, Plant, and Equipment (Detail)  HTML     49K 
52: R50         Property, Plant, and Equipment - Additional         HTML     27K 
                Information (Detail)                                             
26: R51         Intangible Assets and Goodwill - Additional         HTML     33K 
                Information (Detail)                                             
67: R52         Components of Accrued Liabilities (Detail)          HTML     48K 
76: R53         Changes in Initial Product Warranty Accrual and     HTML     41K 
                Expenses Under Initial and Extended Warranties                   
                (Detail)                                                         
51: R54         Accrued Liabilities - Additional Information        HTML     33K 
                (Detail)                                                         
25: R55         Debt - Summary of Principal Outstanding and         HTML     33K 
                Unamortized Discount (Detail)                                    
66: R56         Debt - Additional Information (Detail)              HTML    224K 
75: R57         Debt - Summary of Future Minimum Principal and      HTML     47K 
                Interest Payments (Detail)                                       
53: R58         Leases - Additional Information (Detail)            HTML     64K 
23: R59         Leases - Information related to Right-of-use        HTML     29K 
                Assets and Liabilities (Detail)                                  
58: R60         Leases - Schedule of Maturities of Lease            HTML     37K 
                Liabilities (Detail)                                             
83: R61         Leases - Future Minimum Rental Commitments Under    HTML     44K 
                Lease Agreements (Detail)                                        
36: R62         Commitments and Contingencies - Additional          HTML     57K 
                Information (Detail)                                             
28: R63         Segment Information - Additional Information        HTML     38K 
                (Detail)                                                         
57: R64         Summary of Net Revenue by Geographic Location       HTML     32K 
                (Detail)                                                         
82: R65         Summary of Property, Plant and Equipment by         HTML     33K 
                Geographic Location (Detail)                                     
35: R66         Concentrations - Summary of Net Revenue from        HTML     49K 
                Various Products (Detail)                                        
27: R67         Concentrations - Additional Information (Detail)    HTML     40K 
56: R68         Income Taxes - Additional Information (Detail)      HTML     36K 
84: R69         Subsequent Event - Additional Information (Detail)  HTML     51K 
24: XML         IDEA XML File -- Filing Summary                      XML    152K 
38: EXCEL       IDEA Workbook of Financial Reports                  XLSX     89K 
 9: EX-101.INS  XBRL Instance -- biol-20200331                       XML   2.24M 
11: EX-101.CAL  XBRL Calculations -- biol-20200331_cal               XML    170K 
12: EX-101.DEF  XBRL Definitions -- biol-20200331_def                XML    543K 
13: EX-101.LAB  XBRL Labels -- biol-20200331_lab                     XML   1.33M 
14: EX-101.PRE  XBRL Presentations -- biol-20200331_pre              XML   1.01M 
10: EX-101.SCH  XBRL Schema -- biol-20200331                         XSD    205K 
79: ZIP         XBRL Zipped Folder -- 0001564590-20-023480-xbrl      Zip    165K 


‘EX-10.8’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C: 

Ex. 10.8

 

 

 

 

U.S. Small Business Administration

 

NOTE

 

 

 

 

SBA Loan #

61646970-06

SBA Loan Name

Biolase, Inc.

Date

April 13, 2020

Loan Amount

$2,980,000.00

Interest Rate

1% Fixed

Borrower

Biolase, Inc.

Operating Company

NA

Lender

Pacific Mercantile Bank

 

 

1.

PROMISE TO PAY:

 

 

 

 

 

In return for the Loan, Borrower promises to pay to the order of Lender the amount of

 

 

Two Million Nine Hundred Eighty Thousand and 00/100

Dollars,

 

interest on the unpaid principal balance, and all other amounts required by this Note.

 

 

 

 

 

2.

DEFINITIONS:

 

 

 

“Collateral” means any property taken as security for payment of this Note or any guarantee of this Note.

 

 

 

“Guarantor” means each person or entity that signs a guarantee of payment of this Note.

 

 

 

“Loan” means the loan evidenced by this Note.

 

 

 

“Loan Documents” means the documents related to this loan signed by Borrower, any Guarantor, or anyone who pledges collateral.

 

 

 

“SBA” means the Small Business Administration, an Agency of the United States of America.

 

 

 

 

 

Page 1/6


 

 

 

 

3.

PAYMENT TERMS:

 

 

 

Borrower must make all payments at the place Lender designates. The payment terms for this Note are:

 

 

 

 

 

Borrower must pay interest-only monthly payments of accrued interest at a fixed interest rate of one percent (1.00%) for the term of two years. Principal and accrued interest is due and payable at maturity.

 

 

 

Borrower must pay one payment of interest only on the disbursed principal balance one month from the month of initial disbursement on this Note; payment must be made on the first calendar day in the month it is due.

 

 

 

Borrower must pay interest payments beginning two months from the month of initial disbursement on this Note; payments must be made on the first calendar day in the months they are due.

 

 

 

Borrower will not have to make any payments for six months following the date of disbursement of the loan. Interest will accrue during this six-month deferment and will be due and payable at maturity.

 

 

 

Section 1102 of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) “Paycheck Protection Program” (“PPP”) provides for the forgiveness of up to the full principal amount of the loan and any accrued interest, if the Borrower uses all of the loan proceeds for forgivable purposes, as defined in the CARES Act and implementing regulations, over the eight week period following the date of the loan.

 

 

 

Loan forgiveness will be provided for the sum of documented payroll costs, covered mortgage interest payments, covered rent payments, and covered utilities, however, not more than twenty-five percent (25%) of the forgiven amount may be for non-payroll costs.

 

 

 

If Borrower uses PPP loan proceeds for unauthorized purposes, Borrower will be obligated to repay those amounts plus accrued interest at maturity under the terms and conditions of this Note.

 

 

 

All remaining principal and accrued interest is due and payable two (2) years from date of initial disbursement.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Page 2/6


 

 

 

 

4.

DEFAULT:

 

 

 

Borrower is in default under this Note if Borrower does not make a payment when due under this Note, or if Borrower or Operating Company:

 

 

 

A.

Fails to do anything required by this Note and other Loan Documents;

 

B.

Defaults on any other loan with Lender;

 

C.

Does not preserve, or account to Lender’s satisfaction for, any of the Collateral or its proceeds;

 

D.

Does not disclose, or anyone acting on their behalf does not disclose, any material fact to Lender or SBA;

 

E.

Makes, or anyone acting on their behalf makes, a materially false or misleading representation to Lender or SBA;

 

F.

Defaults on any loan or agreement with another creditor, if Lender believes the default may materially affect Borrower ’s ability to pay this Note;

 

G.

Fails to pay any taxes when due;

 

H.

Becomes the subject of a proceeding under any bankruptcy or insolvency law;

 

I.

Has a receiver or liquidator appointed for any part of their business or property;

 

J.

Makes an assignment for the benefit of creditors;

 

K.

Has any adverse change in financial condition or business operation that Lender believes may materially affect Borrower ’s ability to pay this Note;

 

L.

Reorganizes, merges, consolidates, or otherwise changes ownership or business structure without Lender ’s prior written consent; or

 

M.

Becomes the subject of a civil or criminal action that Lender believes may materially affect Borrower ’s ability to pay this Note.

 

 

 

 

 

5.

LENDER ’S RIGHTS IF THERE IS A DEFAULT:

 

 

 

Without notice or demand and without giving up any of its rights, Lender may:

 

 

 

A.

Require immediate payment of all amounts owing under this Note;

 

B.

Collect all amounts owing from any Borrower or Guarantor;

 

C.

File suit and obtain judgment;

 

D.

Take possession of any Collateral; or

 

E.

Sell, lease, or otherwise dispose of, any Collateral at public or private sale, with or without advertisement.

 

 

 

 

 

6.

LENDER ’S GENERAL POWERS:

 

 

 

Without notice and without Borrower ’s consent, Lender may:

 

 

 

A.

Bid on or buy the Collateral at its sale or the sale of another lienholder, at any price it chooses;

 

B.

Incur expenses to collect amounts due under this Note, enforce the terms of this Note or any other Loan Document, and preserve or dispose of the Collateral. Among other things, the expenses may include payments for property taxes, prior liens, insurance, appraisals, environmental remediation costs, and reasonable attorney ’s fees and costs. If Lender incurs such expenses, it may demand immediate repayment from Borrower or add the expenses to the principal balance;

 

C.

Release anyone obligated to pay this Note;

 

D.

Compromise, release, renew, extend or substitute any of the Collateral; and

 

E.

Take any action necessary to protect the Collateral or collect amounts owing on this Note.

 

 

Page 3/6


 

 

 

 

7.

WHEN FEDERAL LAW APPLIES:

 

 

 

When SBA is the holder, this Note will be interpreted and enforced under federal law, including SBA regulations. Lender or SBA may use state or local procedures for filing papers, recording documents, giving notice, foreclosing liens, and other purposes. By using such procedures, SBA does not waive any federal immunity from state or local control, penalty, tax, or liability. As to this Note, Borrower may not claim or assert against SBA any local or state law to deny any obligation, defeat any claim of SBA, or preempt federal law.

 

 

 

 

8.

SUCCESSORS AND ASSIGNS:

 

 

 

Under this Note, Borrower and Operating Company include the successors of each, and Lender includes its successors and assigns.

 

 

 

 

9.

GENERAL PROVISIONS:

 

 

 

A.

All individuals and entities signing this Note are jointly and severally liable.

 

B.

Borrower waives all suretyship defenses.

 

C.

Borrower must sign all documents necessary at any time to comply with the Loan Documents and to enable Lender to acquire, perfect, or maintain Lender ’s liens on Collateral.

 

D.

Lender may exercise any of its rights separately or together, as many times and in any order it chooses. Lender may delay or forgo enforcing any of its rights without giving up any of them.

 

E.

Borrower may not use an oral statement of Lender or SBA to contradict or alter the written terms of this Note.

 

F.

If any part of this Note is unenforceable, all other parts remain in effect.

 

G.

To the extent allowed by law, Borrower waives all demands and notices in connection with this Note, including presentment, demand, protest, and notice of dishonor. Borrower also waives any defenses based upon any claim that Lender did not obtain any guarantee; did not obtain, perfect, or maintain a lien upon Collateral; impaired Collateral; or did not obtain the fair market value of Collateral at a sale.

 

 

 

 

 

 

Page 4/6


 

 

 

 

10.

STATE-SPECIFIC PROVISIONS:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Page 5/6


 

 

 

 

11.

BORROWER ’S NAME(S) AND SIGNATURE(S):

 

 

 

By signing below, each individual or entity becomes obligated under this Note as Borrower.

 

 

 

BIOLASE, INC

 

 

 

By:

/s/ John R. Beaver

 

 

 

John R. Beaver, EVP/CFO

 

 

Page 6/6


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:5/8/20
4/13/20PRE 14A
For Period end:3/31/208-K
 List all Filings 


28 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/19/24  Biolase, Inc.                     POS AM                 1:1.1M                                   Donnelley … Solutions/FA
 4/11/24  Biolase, Inc.                     POS AM                 3:1.1M                                   Donnelley … Solutions/FA
 3/27/24  Biolase, Inc.                     S-1/A                  5:1.1M                                   Donnelley … Solutions/FA
 3/21/24  Biolase, Inc.                     10-K       12/31/23   99:18M                                    Donnelley … Solutions/FA
 2/09/24  Biolase, Inc.                     S-1/A                  4:3M                                     Donnelley … Solutions/FA
 2/07/24  Biolase, Inc.                     S-1/A                  8:3.3M                                   Donnelley … Solutions/FA
 1/31/24  Biolase, Inc.                     S-1/A                  9:3.2M                                   Donnelley … Solutions/FA
 1/19/24  Biolase, Inc.                     S-1                    3:2.6M                                   Donnelley … Solutions/FA
12/26/23  Biolase, Inc.                     S-1                    4:496K                                   Donnelley … Solutions/FA
 9/11/23  Biolase, Inc.                     S-1/A                  4:868K                                   Donnelley … Solutions/FA
 9/05/23  Biolase, Inc.                     S-1/A       9/01/23    2:830K                                   Donnelley … Solutions/FA
 8/30/23  Biolase, Inc.                     S-1/A                  8:1.3M                                   Donnelley … Solutions/FA
 8/18/23  Biolase, Inc.                     S-1/A                  2:720K                                   Donnelley … Solutions/FA
 8/14/23  Biolase, Inc.                     S-1/A       8/11/23    8:1.3M                                   Donnelley … Solutions/FA
 7/21/23  Biolase, Inc.                     S-1                    3:800K                                   Donnelley … Solutions/FA
 5/24/23  Biolase, Inc.                     S-1/A                  7:1.2M                                   Donnelley … Solutions/FA
 5/22/23  Biolase, Inc.                     S-1/A                  8:1.3M                                   Donnelley … Solutions/FA
 5/18/23  Biolase, Inc.                     S-1/A                  8:1.2M                                   Donnelley … Solutions/FA
 5/04/23  Biolase, Inc.                     S-1                    3:750K                                   Donnelley … Solutions/FA
 3/28/23  Biolase, Inc.                     10-K       12/31/22   90:19M                                    Donnelley … Solutions/FA
 1/03/23  Biolase, Inc.                     S-1/A                  6:1M                                     Donnelley … Solutions/FA
12/12/22  Biolase, Inc.                     S-1/A                  7:1.1M                                   Donnelley … Solutions/FA
11/22/22  Biolase, Inc.                     S-1                    3:655K                                   Donnelley … Solutions/FA
 3/17/22  Biolase, Inc.                     10-K       12/31/21   88:18M                                    Donnelley … Solutions/FA
 3/31/21  Biolase, Inc.                     10-K       12/31/20   88:15M                                    ActiveDisclosure/FA
 2/09/21  Biolase, Inc.                     424B5                  1:495K                                   Donnelley … Solutions/FA
12/15/20  Biolase, Inc.                     424B3                  1:392K                                   Donnelley … Solutions/FA
12/08/20  Biolase, Inc.                     S-1/A                  3:585K                                   Donnelley … Solutions/FA
Top
Filing Submission 0001564590-20-023480   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 1:36:58.1pm ET